OFFICIAL-SOURCE RECALL · UNITED KINGDOM
MHRA Safety Roundup: April 2026 Recall: Assessment Committee (PRAC) issued a recommendation
Use the identifiers printed on your item to determine whether this recall may affect the product you own.
CHECK THE ITEM YOU OWN
Is your product affected?
- Brand
- See official notice
- Product
- MHRA Safety Roundup: April 2026
- Manufacturer
- See official notice
The barcode may identify the product type, while the recall may apply only to certain lots, dates or variants. Check all identifiers listed in the official recall.
Why this product was recalled
Assessment Committee (PRAC) issued a recommendation that medicines containing levamisole be withdrawn from the EU market following a safety review confirming leukoencephalopathy as a rare but serious side effect. This follows an EU-wide review which concluded that the benefits of these medicines no longer outweigh their risks for the treatment of parasitic infections in adults and children. Levamisole is a medicine licenced in the EU and indicated for the treatment of mild parasitic infections in adults and children, and is also thought to be a mild immunosuppressant. Levamisole does not hold a current UK marketing authorisation however, levamisole containing medicines are used in the UK off-label in exceptional circumstances to treat children with frequently relapsing or steroid-dependent nephrotic syndrome, to help maintain remission and lower the steroid dosage. Publication of RSV vaccine factsheet The MHRA has
Hazard
Assessment Committee (PRAC) issued a recommendation that medicines containing levamisole be withdrawn from the EU market following a safety review confirming leukoencephalopathy as a rare but serious side effect. This follows an EU-wide review which concluded that the benefits of these medicines no longer outweigh their risks for the treatment of parasitic infections in adults and children. Levamisole is a medicine licenced in the EU and indicated for the treatment of mild parasitic infections in adults and children, and is also thought to be a mild immunosuppressant. Levamisole does not hold a current UK marketing authorisation however, levamisole containing medicines are used in the UK off-label in exceptional circumstances to treat children with frequently relapsing or steroid-dependent nephrotic syndrome, to help maintain remission and lower the steroid dosage. Publication of RSV vaccine factsheet The MHRA has
Official recall notice
MHRA Safety Roundup: April 2026
Agency: Medicines and Healthcare products Regulatory Agency
Official publication date: April 29, 2026
Read the official UK_MHRA recall notice →Scan products you own
Scan products you own once and let RecallGuard monitor future official recalls.
Scan & Monitor Products